ASC41
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ASC41 is an experimental thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta. It has been studied for the treatment of non-alcoholic fatty liver disease. In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809. In 2024, Ascletis discontinued clinical development of ASC41 following unfavorable Phase II clinical trial results.
ASC41 is an experimental thyromimetic prodrug metabolized in the liver by CYP3A4 to an active form, ASC41-A, that is selective for thyroid hormone receptor beta. It has been studied for the treatment of non-alcoholic fatty liver disease. In 2023, Viking Therapeutics filed a lawsuit against ASC41's developer, Chinese company Ascletis BioScience, accusing it of stealing Viking's trade secrets to develop ASC41 which is allegedly similar to, or identical to, VK2809. In 2024, Ascletis discontinued clinical development of ASC41 following unfavorable Phase II clinical trial results. ==References==
Text derived from https://en.wikipedia.org/w/index.php?oldid=1359039289 under CC BY-SA 4.0; modifications have been made.